These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 15950439

  • 21. Comparison of In Vitro Activity and MIC Distributions between the Novel Oxazolidinone Delpazolid and Linezolid against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis in China.
    Zong Z, Jing W, Shi J, Wen S, Zhang T, Huo F, Shang Y, Liang Q, Huang H, Pang Y.
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844043
    [Abstract] [Full Text] [Related]

  • 22. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis from Shenyang, north of China.
    Liu H, Wang Y, Liu N, Zhao L.
    Indian J Med Microbiol; 2015 Feb; 33 Suppl():164-5. PubMed ID: 25657144
    [No Abstract] [Full Text] [Related]

  • 23. Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis.
    Nam HS, Koh WJ, Kwon OJ, Cho SN, Shim TS.
    Int J Antimicrob Agents; 2009 Jan; 33(1):92-3. PubMed ID: 18789655
    [No Abstract] [Full Text] [Related]

  • 24. In vitro susceptibility testing of levofloxacin and ofloxacin by microtiter plate Alamar blue against multidrug and non multidrug resistant Mycobacterium tuberculosis in Thailand.
    Pracharktam R, Angkananukool K, Vibhagool A.
    J Med Assoc Thai; 2001 Sep; 84(9):1241-5. PubMed ID: 11800295
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis.
    Park IN, Hong SB, Oh YM, Kim MN, Lim CM, Lee SD, Koh Y, Kim WS, Kim DS, Kim WD, Shim TS.
    J Antimicrob Chemother; 2006 Sep; 58(3):701-4. PubMed ID: 16857689
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.
    Barbachyn MR, Hutchinson DK, Brickner SJ, Cynamon MH, Kilburn JO, Klemens SP, Glickman SE, Grega KC, Hendges SK, Toops DS, Ford CW, Zurenko GE.
    J Med Chem; 1996 Feb 02; 39(3):680-5. PubMed ID: 8576910
    [Abstract] [Full Text] [Related]

  • 29. In Vitro Activity of Tedizolid against Mycobacterium tuberculosis.
    Ruiz P, Causse M, Vaquero M, Casal M.
    Antimicrob Agents Chemother; 2019 Apr 02; 63(4):. PubMed ID: 30670412
    [Abstract] [Full Text] [Related]

  • 30. Bacteriostatic or bactericidal effect of linezolid against multiresistant Streptococcus pneumoniae.
    Malm A, Korona-Głowniak I, Biernasiuk A, Kalasiewicz A, Juda M.
    New Microbiol; 2008 Jul 02; 31(3):363-70. PubMed ID: 18843891
    [Abstract] [Full Text] [Related]

  • 31. Antimycobacterial activity of econazole against multidrug-resistant strains of Mycobacterium tuberculosis.
    Ahmad Z, Sharma S, Khuller GK, Singh P, Faujdar J, Katoch VM.
    Int J Antimicrob Agents; 2006 Dec 02; 28(6):543-4. PubMed ID: 17101262
    [Abstract] [Full Text] [Related]

  • 32. In vitro activities of linezolid against multiple Nocardia species.
    Brown-Elliott BA, Ward SC, Crist CJ, Mann LB, Wilson RW, Wallace RJ.
    Antimicrob Agents Chemother; 2001 Apr 02; 45(4):1295-7. PubMed ID: 11257051
    [Abstract] [Full Text] [Related]

  • 33. Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci.
    Livermore DM, Mushtaq S, Warner M, Woodford N.
    J Antimicrob Chemother; 2009 Apr 02; 63(4):713-5. PubMed ID: 19164418
    [Abstract] [Full Text] [Related]

  • 34. Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study.
    Ross JE, Fritsche TR, Sader HS, Jones RN.
    Int J Antimicrob Agents; 2007 Mar 02; 29(3):295-301. PubMed ID: 17239570
    [Abstract] [Full Text] [Related]

  • 35. Activities of linezolid against rapidly growing mycobacteria.
    Wallace RJ, Brown-Elliott BA, Ward SC, Crist CJ, Mann LB, Wilson RW.
    Antimicrob Agents Chemother; 2001 Mar 02; 45(3):764-7. PubMed ID: 11181357
    [Abstract] [Full Text] [Related]

  • 36. Low levels of second-line drug resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Rwanda.
    Umubyeyi A, Rigouts L, Shamputa IC, Dediste A, Struelens M, Portaels F.
    Int J Infect Dis; 2008 Mar 02; 12(2):152-6. PubMed ID: 17950021
    [Abstract] [Full Text] [Related]

  • 37. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.
    Rodríguez JC, Ruiz M, López M, Royo G.
    Int J Antimicrob Agents; 2002 Dec 02; 20(6):464-7. PubMed ID: 12458143
    [Abstract] [Full Text] [Related]

  • 38. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers).
    Jones RN, Fritsche TR, Sader HS, Ross JE.
    Diagn Microbiol Infect Dis; 2007 Nov 02; 59(3):309-17. PubMed ID: 17720350
    [Abstract] [Full Text] [Related]

  • 39. [Antibacterial effect of nitric oxide].
    Coban AY, Bayramoğlu G, Ekinci B, Durupinar B.
    Mikrobiyol Bul; 2003 Nov 02; 37(2-3):151-5. PubMed ID: 14593897
    [Abstract] [Full Text] [Related]

  • 40. Evaluation of the in vitro activity of tigecycline against multiresistant Gram-positive cocci containing tetracycline resistance determinants.
    Borbone S, Lupo A, Mezzatesta ML, Campanile F, Santagati M, Stefani S.
    Int J Antimicrob Agents; 2008 Mar 02; 31(3):209-15. PubMed ID: 17646087
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.